Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081859 | 0.92 | NPC1 (0.53) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3083799 | 0.91 | GAA (0.45) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3085630 | 0.88 | NPC1 (0.55) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3090175 | 0.86 | MAPT (0.50) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3084048 | 0.86 | GAA (0.44) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3083665 | 0.85 | MAPT (0.51) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3072135 | 0.84 | MAPT (0.50) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3089389 | 0.83 | MAPT (0.49) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL30795222 | 0.83 | MAPT (0.45) | MAPTPOLBNPC1GAARAB9A | |
| SCHEMBL3082423 | 0.83 | MAPT (0.45) | MAPTPOLBNPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | claimed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | claimed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GRM5, GRIK5, GRM1 | MAPT 1435/4885POLB 4651/4885NPC1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.